Clinical trials: Liver Steatosis
Fatty Liver Disease, Type 2 Diabetes
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose.
- Conditions
- Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation
- Trial name
- NCT04283942
- Testing
- Intermittent calorie restriction (ICR), Continuous calorie restriction (CCR)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-Alcoholic Fatty Liver Disease
Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.
Nonalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide.
- Trial name
- NAFLD-CARE (NCT04435054)
- Testing
- Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Hospices Civils de Lyon
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)
Approximately 90% of people undergoing bariatric surgery have NAFLD, which is a condition where fat accumulates in the liver and can lead to inflammation and scarring.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Bariatric Surgery Candidate, Obesity, Morbid
- Trial name
- EDISON (NCT03186859)
- Testing
- Roux-en-Y Gastric Bypass (RYGB) surgery, Sleeve Gastrectomy (SG) surgery
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Oxford
Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease
The purpose of this research study is to find out about the usefulness of mindfulness for weight loss and improvement of physical and mental health in people who have non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
- Trial name
- NCT05130346
- Testing
- Mindfulness Based Stress Reduction (MBSR)
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Healthy
A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1.
- Trial name
- NCT00776841
- Testing
- Aramchol
- Where
- Israel
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Galmed Medical Reserch
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease
Aims and objectives: The Investigator aimed to evaluate effect of adjustable intra gastric balloon on non-alcoholic fatty liver disease/non alcoholic steatohepatitis (NAFLD/NASH) with or without diabetes mellitus, who have failed…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04182646
- Testing
- Spartz Balloon
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Asian Institute of Gastroenterology, India
Steatohepatitis, Nonalcoholic
Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis
The goal of this clinical trial is to learn if drug hydroxychloroquine works to treat steatohepatitis in adults. It will also learn about the safety of drug hydroxychloroquine.
- Trial name
- NCT07265297
- Testing
- Hydrochloroquine
- Where
- Taiwan
- Volunteers
- 210 people
- Sponsor
- National Taiwan University Hospital
NAFLD
Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans
High levels of fatty substances in the blood increase the risk of developing heart disease. Investigators know a lot about one of these fatty substances, cholesterol.
- Trial name
- NCT01936779
- Testing
- Dietary supplement: fatty acid
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Obesity & Overweight, Diabetes Mellitus, Type 2
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects…
- Conditions
- Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)
- Trial name
- NCT07884903
- Testing
- No intervention; observational assessment only
- Where
- China
- Volunteers
- 25,974 people
- Sponsor
- Shanxi Bethune Hospital
Intra-abdominal Fat, Metabolic Syndrome
Habitual Diet and Avocado Trial
The Habitual Diet and Avocado Trial will evaluate the effects of providing one avocado per day for recommended consumption over a 6 month period in a cohort of approximately 1000 free-living participants with increased waist…
- Conditions
- Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High
- Trial name
- HAT (NCT03528031)
- Testing
- Intervention Daily Avocado
- Where
- 4 sites in United States
- Volunteers
- 1,008 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Metabolic Associated Fatty Liver Disease, Clinical Features
Clinical Characteristics of Metabolic Associated Fatty Liver Disease
Metabolic associated fatty liver disease (MAFLD), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society.
- Trial name
- NCT06325254
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-Alcoholic Fatty Liver Disease, Gastrointestinal Microbiome
Exercise Study in Subjects With NAFLD
Non-Alcoholic Fatty Liver Disease is the most common cause of chronic liver diseases. The benign non-alcoholic fatty liver, characterized by excessive fat accumulation, can evolve into non-alcoholic steatohepatitis and liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Exercise
- Trial name
- BestTreat (NCT03995056)
- Testing
- high-intensity aerobic interval training
- Where
- Finland
- Volunteers
- 49 people
- Sponsor
- University of Eastern Finland
NAFLD, Cardiac Disease
Cardiac Dysfunction in Patients with Fatty Liver Disease
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease.
- Conditions
- NAFLD, Cardiac Disease, Fatty Liver, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT06386094
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Type 2 Diabetes (T2D)
Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis
The prevalence of fatty liver disease (NAFLD: Non-Alcoholic Fatty Liver Disease or to a more severe degree NASH: Non-Alcoholic SteatoHepatitis) reached 40-70% in subjects with type 2 diabetes (T2D).
- Trial name
- STEATO-POMPE (NCT04270656)
- Testing
- Insulin pump therapy, Multi-injection treatment ( MDI ).
- Where
- 9 sites in France
- Volunteers
- 46 people
- Sponsor
- Nantes University Hospital
Non-Alcoholic Fatty Liver Disease
Probiotics in NASH Patients - PROBILIVER TRIAL
Non-alcoholic Fatty Liver Disease (NAFLD) is characterized by excessive accumulation of lipids in hepatocytes, not associated with alcohol consumption and ranges from hepatic steatosis to steatohepatitis, a form that can progress…
- Trial name
- NASH (NCT03467282)
- Testing
- Probiotic
- Where
- Brazil
- Volunteers
- 46 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Fatty Liver, Fatty Liver, Nonalcoholic
The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease
The aim of this study is to evaluate the effects and safety of a dietary supplement, Zataria multiflora Boiss (Shirazi's Thyme) in the treatment of non alcoholic fatty liver disease (NAFLD).
- Trial name
- ThymeLiv (NCT02983669)
- Testing
- Thyme
- Where
- Iran
- Volunteers
- 86 people
- Sponsor
- Shiraz University of Medical Sciences
Non-Alcoholic Steatohepatitis (NASH)
Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH
Study type :clinical trial Main purpose :esnsure safety and efficacy of Roflumilast to treat patients with Non-Alcoholic Steatohepatitis Background and aim: Non-alcoholic fatty liver disease is the most prevalent chronic liver…
- Trial name
- NCT06677788
- Testing
- Roflumilast 500 Mcg Oral Tablet, Vitamin E capsule
- Where
- Egypt
- Volunteers
- 55 people
- Sponsor
- Tanta University
Type 2 Diabetes, Non Alcholic Fatty Liver Disease
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions ranging from liver steatosis (NAFL), steatohepatitis (NASH), advanced liver fibrosis and ultimately leads to cirrhosis in a significant proportion of…
- Trial name
- B-LIFT (NCT06035874)
- Testing
- Bempedoic acid
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
NASH
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05327127
- Testing
- K-877-ER, CSG452
- Where
- 77 sites in United States, Argentina and 4 more
- Volunteers
- 228 people
- Sponsor
- Kowa Research Institute, Inc.
Heathy Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
The study will evaluate the safety, tolerability, and the pharmacokinetics (PK) of AZD7503 following multiple subcutaneous doses in healthy Japanese participants.
- Trial name
- NCT06093542
- Testing
- AZD7053
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca